Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
ACCRivaroxaban Doesn't Increase Post-ACS Bleeding vs Aspirin: StudyIn GEMINI-ACS-1, bleeding risk did not differ significantly between patients on a P2Y12 inhibitor plus rivaroxaban vs aspirin. But is it really time to throw out aspirin as "the cornerstone" of ACS treatment?
Heartwire from Medscape, March 19, 2017
ACCEvolocumab Added to Statins Cuts CV Events in FOURIER TrialUPDATED // In the heavily anticipated FOURIER outcomes trial, the PCSK9 inhibitor met its primary and key secondary measures. But is it enough to shut down concerns over costs for the medication class?
Heartwire from Medscape, March 17, 2017
Meeting Highlights At A Glance
Top News From ACC 2017: SlideshowHighly anticipated data on PCSK9 inhibitors were featured prominently at this year's scientific sessions.
GAUSS-3: Evolocumab Cuts LDL-C in Statin-Intolerant PatientsUPDATED // "We have established that you can use PCSK9 inhibitors successfully" in this patient population, said the lead
author. "And that has regulatory and practice implications."
First Clinical Trial of CTO Procedures Fails to DeliverGiven the rise of procedures for chronic total coronary occlusions, Dr. Mandrola feels that the decidedly negative DECISION-CTO
trial is the most important study from the second day of ACC.
Ten Quick Thoughts on FOURIERDr Mandrola attended the late-breaking session at ACC and has these 10 quick thoughts on the landmark FOURIER trial.
#ACC17 Best Meeting in Years: Here's WhyDr Melissa Walton-Shirley summarizes what was great about the ACC meeting this year, including some high points in presentations.